Division of Biocon Ltd.
Latest From Nobex Corp.
GenVec's stock price bounced up and down $0.10 in both directions on 25 September when the Gaithersburg, Maryland-based company announced that it will eliminate 23 jobs, or 30% of its work force, but the stock ultimately remained steady, closing at $1.69 per share from $1.68 the day before.
Allena Pharmaceuticals, a new US biotech focused on developing novel non-systemic oral protein therapeutics, has raised $15 million in series A venture capital financing. Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures led the round.
Medgenics, the developer of the biopump delivery system for treating chronic disease, is looking to raise $15-20 million by the middle of 2009. The combination biological/device product aims to improve protein delivery for chronic diseases than existing treatments, starting with Epodure, the delivery of erythropoietin (EPO) for anaemia.
Licensing is not only a mainstream activity for the pharmaceutical industry but also an intensively competitive one. Big pharma companies vie for the best opportunities, pushing up the value of highly sought after products. But how are they to know what the best opportunities are? There are literally thousands of biotech and technology companies all offering 'unique, unmissable' opportunities. This means big companies have to be very selective about which products to evaluate, and this in turn means the biotech companies must ensure that their initial presentation – which may be just 10 to 15 minutes at a bio partnering meeting – is perfectly pitched to attract the audience's attention.
- Large Molecule
- Drug Delivery
- Therapeutic Areas
- Protein Delivery Inc.
- North America
- Parent & Subsidiaries
- Biocon Ltd.
- Senior Management
Vicki Morgan, Exec. Dir., Bus. Dev.
Russell M Savre, VP, Fin. & Admin.
- Contact Info
Phone: (919) 474-0507
617 Davis Dr.
P.O. Box 13940 Durham, NC 27709-3940
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.